Returning for its 3rd year, PREDiCT: Tumor Models San Francisco remains dedicated to revealing model-based strategies adding immediate value to emerging IO programs.
With new speakers, fresh case studies, and a more interactive format to the agenda, this is your opportunity to plug into a ready-made network of pioneering biotech and developers redefining this area.
Leave with actionable takeaways on model utility and applicability. Dive into the use of both emerging and classical model systems and understand how they can correctly be used to support your translational decision making.
Prices:
Conference Only : USD 2499.0,
Conference + 3 Workshops: USD 4296.0
Speakers: James Hodge, Deputy Chief Tumor Immunology and Biology, Senior Investigator, Head, Recombinant Vaccine Group, National Cancer Institute, Barbara Joyce- Shaikh, Associate Principal Scientist, Merck and Co, Peter King, Principal Scientist PDS-PDM - Imaging, Janssen Research and Development, John Westwick, CEO, Resonant Therapeutics, Inc, Joshua Breunig, Associate Professor and Board of Governors Regenerative Medicine, Cedars-Sinai Medical Center
Returning for its 3rd year, PREDiCT: Tumor Models San Francisco remains dedicated to revealing model-based strategies adding immediate value to emerging IO programs.
With new speakers, fresh case studies, and a more interactive format to the agenda, this is your opportunity to plug into a ready-made network of pioneering biotech and developers redefining this area.
Leave with actionable takeaways on model utility and applicability. Dive into the use of both emerging and classical model systems and understand how they can correctly be used to support your translational decision making.
Prices:
Conference Only : USD 2499.0,
Conference + 3 Workshops: USD 4296.0
Speakers: James Hodge, Deputy Chief Tumor Immunology and Biology, Senior Investigator, Head, Recombinant Vaccine Group, National Cancer Institute, Barbara Joyce- Shaikh, Associate Principal Scientist, Merck and Co, Peter King, Principal Scientist PDS-PDM - Imaging, Janssen Research and Development, John Westwick, CEO, Resonant Therapeutics, Inc, Joshua Breunig, Associate Professor and Board of Governors Regenerative Medicine, Cedars-Sinai Medical Center
read more
show less